Leg Ulcers in Patients with Myeloproliferative Disorders: Disease- or Treatment-Related?
Leg ulcers are a relatively frequent problem in patients with myeloproliferative disorders under treatment with hydroxyurea (HU). The pathogenesis is currently unknown and may be multifactorial. Concomitant arterial or venous disease may play a contributing role in the development of these wounds. V...
Gespeichert in:
| Veröffentlicht in: | Dermatology (Basel) 2000-01, Vol.200 (1), p.45-48 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 48 |
|---|---|
| container_issue | 1 |
| container_start_page | 45 |
| container_title | Dermatology (Basel) |
| container_volume | 200 |
| creator | Bader, U. Banyai, M. Böni, R. Burg, G. Hafner, J. |
| description | Leg ulcers are a relatively frequent problem in patients with myeloproliferative disorders under treatment with hydroxyurea (HU). The pathogenesis is currently unknown and may be multifactorial. Concomitant arterial or venous disease may play a contributing role in the development of these wounds. Vasculitis, cryoglobulinemia and pyoderma gangrenosum should be considered if typical clinical signs are present. We report on 3 patients with myeloproliferative disorders who developed HU-induced leg ulcers and review the literature. HU-induced leg ulcers share clinical features which can help to differentiate them from leg ulcers of other etiologies: occurrence under long-term treatment with HU at a dose of at least 1 g/day, localization in the malleolar region and spontaneous healing when HU is discontinued. We conclude that differentiation between disease-related and treatment-induced leg ulcers can be difficult and may not always be possible. In HU-induced leg ulcers, cessation of the drug typically leads to wound healing. |
| doi_str_mv | 10.1159/000018315 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_20920322</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20920322</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-41bdce99a8908457f936a729aa08b21da2c3d2026a86f97d37363780435a83523</originalsourceid><addsrcrecordid>eNpt0ElLxDAUB_AgisvowbMgRUTwUM3SZvEiMq4wosgI3sqb9lWrXcako_jtzdhhRsRcEvJ-efnzCNlm9Iix2BxTv5gWLF4i6yziLDRa8GV_9rehljJeIxvOvXrFtTKrZI1RqZlk0Tp5GuBz8FimaF1Q1ME9tAXWrQs-i_YluP3CshnbpixytL7ygcF54RqbeX0yPSI4DIPGBkOL0Fb-ZfiAJbSYnW6SlRxKh1uzvUceLy-G_etwcHd10z8bhGnE4jaM2ChL0RjQhuooVrkREhQ3AFSPOMuApyLjlEvQMjcqE0pIoTSNRAxaxFz0yEHX1-d8n6Brk6pwKZYl1NhMXMKp4VTwKdz7A1-bia19toSryGilYunRYYdS2zhnMU_GtqjAfiWMJtNZJ_NZe7s7azgZVZj9kt1wPdifAXAplLmFOi3cwnEtI24Wwd7APqOd188fbn8-SsZZ7tHOv6iL8g3uUJf9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>274987756</pqid></control><display><type>article</type><title>Leg Ulcers in Patients with Myeloproliferative Disorders: Disease- or Treatment-Related?</title><source>MEDLINE</source><source>Karger Journals</source><creator>Bader, U. ; Banyai, M. ; Böni, R. ; Burg, G. ; Hafner, J.</creator><creatorcontrib>Bader, U. ; Banyai, M. ; Böni, R. ; Burg, G. ; Hafner, J.</creatorcontrib><description>Leg ulcers are a relatively frequent problem in patients with myeloproliferative disorders under treatment with hydroxyurea (HU). The pathogenesis is currently unknown and may be multifactorial. Concomitant arterial or venous disease may play a contributing role in the development of these wounds. Vasculitis, cryoglobulinemia and pyoderma gangrenosum should be considered if typical clinical signs are present. We report on 3 patients with myeloproliferative disorders who developed HU-induced leg ulcers and review the literature. HU-induced leg ulcers share clinical features which can help to differentiate them from leg ulcers of other etiologies: occurrence under long-term treatment with HU at a dose of at least 1 g/day, localization in the malleolar region and spontaneous healing when HU is discontinued. We conclude that differentiation between disease-related and treatment-induced leg ulcers can be difficult and may not always be possible. In HU-induced leg ulcers, cessation of the drug typically leads to wound healing.</description><identifier>ISSN: 1018-8665</identifier><identifier>EISSN: 1421-9832</identifier><identifier>DOI: 10.1159/000018315</identifier><identifier>PMID: 10681614</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Aged ; Aged, 80 and over ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Case Report ; Female ; Follow-Up Studies ; Hematologic and hematopoietic diseases ; Humans ; Hydroxyurea - adverse effects ; Hydroxyurea - therapeutic use ; Leg Ulcer - chemically induced ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Myeloproliferative Disorders - drug therapy ; Polycythemia - drug therapy ; Thrombocytosis - drug therapy</subject><ispartof>Dermatology (Basel), 2000-01, Vol.200 (1), p.45-48</ispartof><rights>2000 S. Karger AG, Basel</rights><rights>2000 INIST-CNRS</rights><rights>Copyright (R) 2000 S. Karger AG, Basel</rights><rights>Copyright (c) 2000 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-41bdce99a8908457f936a729aa08b21da2c3d2026a86f97d37363780435a83523</citedby><cites>FETCH-LOGICAL-c415t-41bdce99a8908457f936a729aa08b21da2c3d2026a86f97d37363780435a83523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2427,4021,27921,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1286429$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10681614$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bader, U.</creatorcontrib><creatorcontrib>Banyai, M.</creatorcontrib><creatorcontrib>Böni, R.</creatorcontrib><creatorcontrib>Burg, G.</creatorcontrib><creatorcontrib>Hafner, J.</creatorcontrib><title>Leg Ulcers in Patients with Myeloproliferative Disorders: Disease- or Treatment-Related?</title><title>Dermatology (Basel)</title><addtitle>Dermatology</addtitle><description>Leg ulcers are a relatively frequent problem in patients with myeloproliferative disorders under treatment with hydroxyurea (HU). The pathogenesis is currently unknown and may be multifactorial. Concomitant arterial or venous disease may play a contributing role in the development of these wounds. Vasculitis, cryoglobulinemia and pyoderma gangrenosum should be considered if typical clinical signs are present. We report on 3 patients with myeloproliferative disorders who developed HU-induced leg ulcers and review the literature. HU-induced leg ulcers share clinical features which can help to differentiate them from leg ulcers of other etiologies: occurrence under long-term treatment with HU at a dose of at least 1 g/day, localization in the malleolar region and spontaneous healing when HU is discontinued. We conclude that differentiation between disease-related and treatment-induced leg ulcers can be difficult and may not always be possible. In HU-induced leg ulcers, cessation of the drug typically leads to wound healing.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Case Report</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Hydroxyurea - adverse effects</subject><subject>Hydroxyurea - therapeutic use</subject><subject>Leg Ulcer - chemically induced</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Myeloproliferative Disorders - drug therapy</subject><subject>Polycythemia - drug therapy</subject><subject>Thrombocytosis - drug therapy</subject><issn>1018-8665</issn><issn>1421-9832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0ElLxDAUB_AgisvowbMgRUTwUM3SZvEiMq4wosgI3sqb9lWrXcako_jtzdhhRsRcEvJ-efnzCNlm9Iix2BxTv5gWLF4i6yziLDRa8GV_9rehljJeIxvOvXrFtTKrZI1RqZlk0Tp5GuBz8FimaF1Q1ME9tAXWrQs-i_YluP3CshnbpixytL7ygcF54RqbeX0yPSI4DIPGBkOL0Fb-ZfiAJbSYnW6SlRxKh1uzvUceLy-G_etwcHd10z8bhGnE4jaM2ChL0RjQhuooVrkREhQ3AFSPOMuApyLjlEvQMjcqE0pIoTSNRAxaxFz0yEHX1-d8n6Brk6pwKZYl1NhMXMKp4VTwKdz7A1-bia19toSryGilYunRYYdS2zhnMU_GtqjAfiWMJtNZJ_NZe7s7azgZVZj9kt1wPdifAXAplLmFOi3cwnEtI24Wwd7APqOd188fbn8-SsZZ7tHOv6iL8g3uUJf9</recordid><startdate>200001</startdate><enddate>200001</enddate><creator>Bader, U.</creator><creator>Banyai, M.</creator><creator>Böni, R.</creator><creator>Burg, G.</creator><creator>Hafner, J.</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>200001</creationdate><title>Leg Ulcers in Patients with Myeloproliferative Disorders: Disease- or Treatment-Related?</title><author>Bader, U. ; Banyai, M. ; Böni, R. ; Burg, G. ; Hafner, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-41bdce99a8908457f936a729aa08b21da2c3d2026a86f97d37363780435a83523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Case Report</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Hydroxyurea - adverse effects</topic><topic>Hydroxyurea - therapeutic use</topic><topic>Leg Ulcer - chemically induced</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Myeloproliferative Disorders - drug therapy</topic><topic>Polycythemia - drug therapy</topic><topic>Thrombocytosis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bader, U.</creatorcontrib><creatorcontrib>Banyai, M.</creatorcontrib><creatorcontrib>Böni, R.</creatorcontrib><creatorcontrib>Burg, G.</creatorcontrib><creatorcontrib>Hafner, J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Dermatology (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bader, U.</au><au>Banyai, M.</au><au>Böni, R.</au><au>Burg, G.</au><au>Hafner, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Leg Ulcers in Patients with Myeloproliferative Disorders: Disease- or Treatment-Related?</atitle><jtitle>Dermatology (Basel)</jtitle><addtitle>Dermatology</addtitle><date>2000-01</date><risdate>2000</risdate><volume>200</volume><issue>1</issue><spage>45</spage><epage>48</epage><pages>45-48</pages><issn>1018-8665</issn><eissn>1421-9832</eissn><abstract>Leg ulcers are a relatively frequent problem in patients with myeloproliferative disorders under treatment with hydroxyurea (HU). The pathogenesis is currently unknown and may be multifactorial. Concomitant arterial or venous disease may play a contributing role in the development of these wounds. Vasculitis, cryoglobulinemia and pyoderma gangrenosum should be considered if typical clinical signs are present. We report on 3 patients with myeloproliferative disorders who developed HU-induced leg ulcers and review the literature. HU-induced leg ulcers share clinical features which can help to differentiate them from leg ulcers of other etiologies: occurrence under long-term treatment with HU at a dose of at least 1 g/day, localization in the malleolar region and spontaneous healing when HU is discontinued. We conclude that differentiation between disease-related and treatment-induced leg ulcers can be difficult and may not always be possible. In HU-induced leg ulcers, cessation of the drug typically leads to wound healing.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>10681614</pmid><doi>10.1159/000018315</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1018-8665 |
| ispartof | Dermatology (Basel), 2000-01, Vol.200 (1), p.45-48 |
| issn | 1018-8665 1421-9832 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20920322 |
| source | MEDLINE; Karger Journals |
| subjects | Aged Aged, 80 and over Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Case Report Female Follow-Up Studies Hematologic and hematopoietic diseases Humans Hydroxyurea - adverse effects Hydroxyurea - therapeutic use Leg Ulcer - chemically induced Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Myeloproliferative Disorders - drug therapy Polycythemia - drug therapy Thrombocytosis - drug therapy |
| title | Leg Ulcers in Patients with Myeloproliferative Disorders: Disease- or Treatment-Related? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T13%3A33%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Leg%20Ulcers%20in%20Patients%20with%20Myeloproliferative%20Disorders:%20Disease-%20or%20Treatment-Related?&rft.jtitle=Dermatology%20(Basel)&rft.au=Bader,%20U.&rft.date=2000-01&rft.volume=200&rft.issue=1&rft.spage=45&rft.epage=48&rft.pages=45-48&rft.issn=1018-8665&rft.eissn=1421-9832&rft_id=info:doi/10.1159/000018315&rft_dat=%3Cproquest_pubme%3E20920322%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=274987756&rft_id=info:pmid/10681614&rfr_iscdi=true |